JOHNSON & JOHNSON
Johnson & Johnson is a healthcare holding company whose operating companies research, develop, manufacture and sell products focused on human health and well-being. It operates in virtually all countries and is headquartered in New Brunswick, New Jersey. Its two business segments are Innovative Medicine and MedTech. Innovative Medicine develops prescription medicines across areas including oncology, immunology, neuroscience, infectious diseases, pulmonary hypertension, and cardiovascular and metabolism. Products include DARZALEX, STELARA, TREMFYA and other medicines distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals. MedTech develops and manufactures products for cardiovascular care, orthopaedics, surgery and vision, including Abiomed technologies, Mentor products, ACUVUE contact lenses and TECNIS intraocular lenses. Its products are distributed to wholesalers, hospitals and retailers and used by healthcare professionals and healthcare systems.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $JNJ in the last 30 days.
See all $JNJ insider activity →Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.
Plaintiffs in a Connecticut case urge the appellate court to uphold a $25 million verdict against Johnson & Johnson, claiming the trial court correctly limited J&J's expert testimony and instructed the jury on liability. They argue evidence shows J&J's Baby Powder caused their injuries.
Anthropic spent $9.5B on R&D in Q3, surpassing Microsoft's $9.05B, according to its IPO prospectus. Only Alphabet, Meta, Apple, and Samsung reported higher R&D. Anthropic's R&D is primarily compute and infrastructure costs, with significant cloud service provider spending. The company has $131.8B in cash and $895.4B in purchase commitments.
Over the past 7 days, AlphAI's AI scored 23 news stories mentioning JNJ (JOHNSON & JOHNSON). Coverage has skewed bullish: 15 bullish, 6 neutral, and 2 bearish.
Recent JNJ coverage spans regulation, financial news and earnings.
Deal-talk termination reduces M&A optionality for DePuy Synthes orthopaedics, leaving J&J to address knee and hip drivers organically.
The appeal could increase liability exposure for JNJ, prompting investors to reassess risk.
Comparator only; no new JNJ-specific catalyst.
The article is broadly positive on J&J’s external innovation engine, but it is not a new financial catalyst; it mainly informs longer-term pipeline strategy.
The approval adds a modest revenue stream and could improve investor sentiment toward JNJ.
AlphAI scores every news story that mentions JNJ with an AI model for sentiment and relevance, and aggregates insider trades from JOHNSON & JOHNSON's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.
Plaintiffs in a Connecticut case urge the appellate court to uphold a $25 million verdict against Johnson & Johnson, claiming the trial court correctly limited J&J's expert testimony and instructed the jury on liability. They argue evidence shows J&J's Baby Powder caused their injuries.
Anthropic spent $9.5B on R&D in Q3, surpassing Microsoft's $9.05B, according to its IPO prospectus. Only Alphabet, Meta, Apple, and Samsung reported higher R&D. Anthropic's R&D is primarily compute and infrastructure costs, with significant cloud service provider spending. The company has $131.8B in cash and $895.4B in purchase commitments.
Johnson & Johnson's incubator program, JLabs, has supported around 1,200 biotech companies since 2012, with over 500 leading to collaborations. About 60% of active companies have deals or discussions with J&J. The company has acquired Serotiny, a biotech focused on cell and gene therapy, and is evolving its strategy to focus on select early-stage companies. JLabs has reduced its physical presence but maintains virtual support and regional innovation centers.
Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.
A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.
Johnson & Johnson presented positive clinical data on Impella heart pumps at TCT 2026, showing lower mortality rates in HRPCI patients. The data, from 1,379 patients, contrasts with recent CHIP-BCIS3 study results. The findings highlight real-world outcomes in U.S. and European hospitals.
Johnson & Johnson (JNJ) reported a $7 billion charge in Q3 2026 due to talc litigation and growth investments, reducing earnings. Despite this, the company raised its full-year revenue and earnings guidance. The charge includes a $3 billion initial payment for a talc settlement and expenses for acquisitions and partnerships. JNJ's revenue grew nearly 6% quarterly, and its long-term dividend track record remains intact.
AstraZeneca (AZN) and Daiichi Sankyo (4568.T) won EU approval for Enhertu in breast cancer. Pfizer (PFE) expanded Talzenna-Xtandi use in prostate cancer. AbbVie (ABBV) got FDA approval for subcutaneous SKYRIZI in Crohn's disease. Artiva (ARTV) to cut 94% of workforce after halting AlloNK development. Tango (TNGX) plans 14% layoffs. Rakovina (RKV.V) and Celvion used AI to prioritize cancer types for ATR inhibitor. 60 Degrees (SXTP) partners for alpha-gal syndrome research.
Johnson & Johnson's investigational therapy JNJ-6143 showed significant PSA declines and radiographic responses in heavily pretreated mCRPC patients, according to phase 1 study results. Among 38 patients, 77% had a confirmed PSA decline of at least 50%, and 48% had a decline of at least 90%. The confirmed objective response rate was 69% in patients with measurable disease. The study identified 50 mg once daily as the recommended phase 2 dose, and a phase 2 study has been initiated.
